Orloff departs FDA

Executive Summary

Metabolic & Endocrine Disorders Division Director David Orloff will step down Dec. 30 after 11 years with FDA to become the medical director of contract research organization Medpace, Inc. Orloff announced his resignation Nov. 29. Division Deputy Director Mary Parks will take over as acting director Jan. 1 until a permanent successor is named. Orloff, who oversaw FDA's review of Bristol-Myers Squibb's Pargluva, is one of several top officials to resign since summer, following the departures of Commissioner Lester Crawford and Office of Women's Health Director Susan Wood...